Recent advances in xenotransplantation

The major barrier to clinically successful pig-to-human xenotransplantation is antibody- and complement-dependent hyperacute rejection, known to be due to host anti-Galα(1,3)Gal antibodies. Strategies aimed at eliminating hyperacute rejection involve transgenic approaches to eliminate or reduce expr...

Full description

Saved in:
Bibliographic Details
Published in:Current Opinion in Immunology 1999-10, Vol.11 (5), p.527-531
Main Authors: Sandrin, Mauro S, McKenzie, Ian FC
Format: Article
Language:English
Subjects:
Animals
Animals, Genetically Modified - immunology
Antibody
Antigen Presentation
CD1
Disaccharides - biosynthesis
Disaccharides - immunology
Endogenous Retroviruses
Epitopes
Graft Rejection - prevention & control
Humans
Pig models
Swine - genetics
Swine - immunology
Swine - virology
Tolerance
Transplantation, Heterologous - immunology
Xenotransplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The major barrier to clinically successful pig-to-human xenotransplantation is antibody- and complement-dependent hyperacute rejection, known to be due to host anti-Galα(1,3)Gal antibodies. Strategies aimed at eliminating hyperacute rejection involve transgenic approaches to eliminate or reduce expression of Galα(1,3)Gal or to reduce complement activation; some of these are now in clinical trials in primates. Another important role of Galα(1,3)Gal that is becoming more evident is in antibody-dependent and -independent xenograft rejection that is mediated by natural killer cells and monocytes.
ISSN:0952-7915
1879-0372
DOI:10.1016/S0952-7915(99)00011-4